Investor Presentaiton
AROA FY22 Outlook
$
E
00
NZ$30-$33m¹
product sales FY22
39-53% higher than FY21
இ
GM
improvement
•
.
•
AROA is well placed for FY22 following an improved second half of FY21 and sales transition
Focused on building our US commercial operations over next 24 months to drive revenue growth to
take advantage of the opportunities presented by our expanded product portfolio
TELA Bio sales expected to deliver strong growth based on their revenue guidance of 48% to 65%
growth in CY21 compared to CY20
EBITDA will be negative (as previously forecasted) as a result of increased investment into its sales force
(announced in February 2021)
1Guidance subject to no resurgence of COVID-19 in the US, continued improvement in US medical procedure numbers & TELA Bio sales performance. It assumes an average $NZD-$USD exchange rate of
US$0.72
TM
AROA
33View entire presentation